Confarma

Board of Directors

Board of Directors

  • Luzi von Bidder

    President of the Board

    Luzi Andreas von Bidder is President of the Board and currently on the Board of several other private healthcare companies, including Ferring Pharmaceuticals. He was until recently Chairman of the Swiss listed company Acino Holding AG. Prior to Acino, he served as Chairman and Chief Executive Officer of Novartis Ophthalmics AG and as a member of the Novartis Pharma Executive Committee. He is a founder of two healthcare start-ups and has extensive experience in the M&A field. Luzi graduated in Economics from HSG University of St. Gallen.

  • Mike Baronian

    Member of the Board

    Mike Baronian is a Board Member with long-standing experience in the pharmaceutical industry. He joined Solvias in 2005 from Tecan, where he was Chairman of the life sciences robotics company. Since 2003, he has run his own API and drug product company AZAD based in Toffen, Switzerland. From 2000 – 2002 he was the CEO of Asklia, a Veterinary and Dental Company in Belp, Switzerland, and before that CEO of the Central Laboratories in Bern, a not-for-profit institution founded by the Swiss Red Cross. Between 1990 and 1997, he held positions with increasing responsibility at the Johnson & Johnson family of companies. Mike holds a bachelor’s degree in commerce, with majors in Finance and Business Administration, from Concordia University in Montreal, Canada.

  • Christian Leemann

    Member of the Board

    Christian H. Leemann joined the Board in 2011. Based in Basel, he is currently Managing Director of CHEMGO Organica AG and its subsidiary P.H. Stehelin & Cie. Previously, he held a number of roles at Lonza including Vice President, Bulk Pharmaceuticals and Intermediates. With over 30 years of management experience, he has acquired an in-depth knowledge of the pharmaceutical, agrochemical and fine chemical industries and is expert in related service businesses such as distribution, sourcing, consulting. Christian has an MS (dipl. Ing ETH) in Chemical Engineering from the Swiss Institute of Technology in Zurich and an MBA from University of Southern California in Los Angeles.

  • Sandra Neumann

    Member of the Board

    Sandra Neumann joined the Board in April 2016. She brings 10  years of experience in the pharmaceutical and medtech industry with her. Sandra is CEO and founder of Peripal AG, a company developing a medical device for the home dialysis market. In her previous role, she was General Manager Renal for Baxter AG in Switzerland. She held several commercial, operational, and strategic roles within the Baxter European headquarters, worked for McKinsey & Company, and in the biomaterials industry. Sandra graduated in biochemistry and received her PhD from ETH Zürich in 2003.

  • Hansjörg Walther

    Member of the Board

    Hansjörg Walther is Member of the Board since 2004, with extensive knowledge and experience in analytical chemistry, mass spectrometry, quality control, quality management, quality assurance, ISO 9001, GLP, GMP, leadership, turnaround management and M&A. As a founding member of Solvias he participated in the successful spin-off and management buyout in 1999, and led analytical and central scientific services and project management of analytical research. Hansjörg was CEO of Solvias from 2003 to 2014. He has a PhD in Organic Chemistry/Mass Spectrometry from University of Bern, where he also held postdoctoral positions as well as in USA.